Logo image of MAIA

MAIA BIOTECHNOLOGY INC (MAIA) Stock Fundamental Analysis

USA - NYSE Arca - NYSEARCA:MAIA - US5526411021 - Common Stock

1.33 USD
-0.12 (-8.28%)
Last: 12/30/2025, 8:04:00 PM
1.35 USD
+0.02 (+1.5%)
After Hours: 12/30/2025, 8:04:00 PM
Fundamental Rating

2

MAIA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. While MAIA seems to be doing ok healthwise, there are quite some concerns on its profitability. MAIA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MAIA has reported negative net income.
MAIA had a negative operating cash flow in the past year.
MAIA had negative earnings in each of the past 5 years.
In the past 5 years MAIA always reported negative operating cash flow.
MAIA Yearly Net Income VS EBIT VS OCF VS FCFMAIA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

The Return On Assets of MAIA (-146.41%) is worse than 84.91% of its industry peers.
MAIA has a worse Return On Equity (-417.16%) than 75.28% of its industry peers.
Industry RankSector Rank
ROA -146.41%
ROE -417.16%
ROIC N/A
ROA(3y)-208.41%
ROA(5y)-324.93%
ROE(3y)-1657.13%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MAIA Yearly ROA, ROE, ROICMAIA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 2K -2K -4K

1.3 Margins

MAIA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MAIA Yearly Profit, Operating, Gross MarginsMAIA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, MAIA has more shares outstanding
MAIA has more shares outstanding than it did 5 years ago.
There is no outstanding debt for MAIA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MAIA Yearly Shares OutstandingMAIA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
MAIA Yearly Total Debt VS Total AssetsMAIA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -13.07, we must say that MAIA is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -13.07, MAIA is doing worse than 77.36% of the companies in the same industry.
There is no outstanding debt for MAIA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.07
ROIC/WACCN/A
WACCN/A
MAIA Yearly LT Debt VS Equity VS FCFMAIA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M -10M -15M

2.3 Liquidity

MAIA has a Current Ratio of 2.19. This indicates that MAIA is financially healthy and has no problem in meeting its short term obligations.
MAIA has a worse Current ratio (2.19) than 74.91% of its industry peers.
A Quick Ratio of 2.19 indicates that MAIA has no problem at all paying its short term obligations.
MAIA has a worse Quick ratio (2.19) than 72.26% of its industry peers.
Industry RankSector Rank
Current Ratio 2.19
Quick Ratio 2.19
MAIA Yearly Current Assets VS Current LiabilitesMAIA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

MAIA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.72%, which is quite impressive.
EPS 1Y (TTM)46.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-145.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

MAIA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 106.17% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y30.75%
EPS Next 2Y16.37%
EPS Next 3Y114.3%
EPS Next 5Y106.17%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MAIA Yearly Revenue VS EstimatesMAIA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 100M 200M 300M 400M
MAIA Yearly EPS VS EstimatesMAIA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 0 5 10 15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

MAIA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MAIA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MAIA Price Earnings VS Forward Price EarningsMAIA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MAIA Per share dataMAIA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

MAIA's earnings are expected to grow with 114.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.37%
EPS Next 3Y114.3%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MAIA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

MAIA BIOTECHNOLOGY INC

NYSEARCA:MAIA (12/30/2025, 8:04:00 PM)

After market: 1.35 +0.02 (+1.5%)

1.33

-0.12 (-8.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2025-11-07/amc
Earnings (Next)03-19 2026-03-19/amc
Inst Owners6.41%
Inst Owner Change3.89%
Ins Owners12.31%
Ins Owner Change8.08%
Market Cap49.25M
Revenue(TTM)N/A
Net Income(TTM)-16.17M
Analysts82.86
Price Target12.38 (830.83%)
Short Float %5.72%
Short Ratio2.28
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.66%
Min EPS beat(2)12.85%
Max EPS beat(2)26.47%
EPS beat(4)4
Avg EPS beat(4)44.6%
Min EPS beat(4)12.85%
Max EPS beat(4)72.7%
EPS beat(8)6
Avg EPS beat(8)22.01%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-13.32%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-2.78%
EPS NY rev (3m)-2.78%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 12.7
P/tB 12.7
EV/EBITDA N/A
EPS(TTM)-0.73
EYN/A
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS0
BVpS0.1
TBVpS0.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -146.41%
ROE -417.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-208.41%
ROA(5y)-324.93%
ROE(3y)-1657.13%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.19
Quick Ratio 2.19
Altman-Z -13.07
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-145.45%
EPS Next Y30.75%
EPS Next 2Y16.37%
EPS Next 3Y114.3%
EPS Next 5Y106.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.05%
EBIT Next 3YN/A
EBIT Next 5Y38.76%
FCF growth 1Y-23.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.69%
OCF growth 3YN/A
OCF growth 5YN/A

MAIA BIOTECHNOLOGY INC / MAIA FAQ

What is the fundamental rating for MAIA stock?

ChartMill assigns a fundamental rating of 2 / 10 to MAIA.


Can you provide the valuation status for MAIA BIOTECHNOLOGY INC?

ChartMill assigns a valuation rating of 1 / 10 to MAIA BIOTECHNOLOGY INC (MAIA). This can be considered as Overvalued.


What is the profitability of MAIA stock?

MAIA BIOTECHNOLOGY INC (MAIA) has a profitability rating of 0 / 10.


How financially healthy is MAIA BIOTECHNOLOGY INC?

The financial health rating of MAIA BIOTECHNOLOGY INC (MAIA) is 5 / 10.